Additional evidence for this clinicopathologic staging of AD was demonstrated in recent studies using in vivo tau positron emission tomography (PET) with [18F]Flortaucipir (Scholl et al., 2016; Schwarz et al., 2018). Here, MAPT is linked to Alzheimer disease.